{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=no+drug&page=27",
    "query": {
      "intervention": "no drug",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 3890,
    "total_pages": 389,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=no+drug&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=no+drug&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T04:52:03.827Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01520909",
      "title": "Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 92,
      "start_date": "2012-03",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2015-03-10",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520909"
    },
    {
      "nct_id": "NCT03968393",
      "title": "Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stroke",
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Non-vitamin K oral anticoagulant (NOAC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Population Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 2270,
      "start_date": "2019-06-14",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03968393"
    },
    {
      "nct_id": "NCT06377033",
      "title": "Using the EHR to Advance Genomic Medicine Across a Diverse Health System",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Genetic Predisposition",
        "Paraganglioma",
        "Pheochromocytoma",
        "ALS",
        "Parkinson Disease",
        "Polyneuropathies",
        "Frontotemporal Dementia",
        "Alzheimer Disease",
        "Cardiomyopathy Non-ischemic",
        "Thoracic Aortic Aneurysm"
      ],
      "interventions": [
        {
          "name": "Behavioral nudge",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2024-06-10",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06377033"
    },
    {
      "nct_id": "NCT05053971",
      "title": "Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Locally Advanced Pancreatic Carcinoma",
        "Metastatic Pancreatic Carcinoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Pancreatic Carcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Unresectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "BET Bromodomain Inhibitor ZEN-3694",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Core Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Entinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2022-11-16",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Gainesville, Florida • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05053971"
    },
    {
      "nct_id": "NCT06075771",
      "title": "Dopaminergic Therapy for Anhedonia - 2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anhedonia",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Carbidopa Levodopa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 70,
      "start_date": "2023-11-21",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06075771"
    },
    {
      "nct_id": "NCT01338298",
      "title": "Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperprolactinemia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2011-01",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 1,
      "location_summary": "Catonsville, Maryland",
      "locations": [
        {
          "city": "Catonsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01338298"
    },
    {
      "nct_id": "NCT04197687",
      "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Multi-epitope HER2 Peptide Vaccine TPIV100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 480,
      "start_date": "2020-02-20",
      "completion_date": "2025-01-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 30,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197687"
    },
    {
      "nct_id": "NCT05458544",
      "title": "[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "[177Lu]Ludotadipep 3.7 GBq",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FutureChem",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2022-09-01",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-29",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Gettysburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05458544"
    },
    {
      "nct_id": "NCT03374332",
      "title": "Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Gemtuzumab Ozogamicin (GO)",
          "type": "DRUG"
        },
        {
          "name": "Donor Leukocytes",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-12-31",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03374332"
    },
    {
      "nct_id": "NCT02389998",
      "title": "Efficacy of Open Label Placebo in Children With FGIDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Functional Abdominal Pain",
        "Functional Dyspepsia",
        "Irritable Bowel Syndrome",
        "Functional Gastrointestinal Disorders"
      ],
      "interventions": [
        {
          "name": "Placebo Suspension",
          "type": "OTHER"
        },
        {
          "name": "Hyoscyamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "8 Years to 21 Years"
      },
      "enrollment_count": 31,
      "start_date": "2014-07",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-10-16T04:52:03.827Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02389998"
    }
  ]
}